This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cyberonics Announces Results From The E-36 Study Of VNS TherapyA® Delivered By The AspireSR™ Generator

Stocks in this article: CYBX

HOUSTON, Dec. 8, 2013 /PRNewswire/ --  Cyberonics, Inc. (NASDAQ: CYBX) announced today that results from the E-36 clinical study of the AspireSR generator were presented at the annual  AES Meeting, taking place December 6-10 at the Walter E. Washington Convention Center in Washington, D.C.  

Paul Boon, M.D., Ph.D., Senior Full Professor of Neurology and Director of Ghent Institute for Neuroscience at Ghent University presented results of the study entitled, "Vagus Nerve Stimulation Triggered by Cardiac-Based Seizure Detection, A Prospective Multicenter Study," on December 7, 2013.  The study ( NCT01325623) was designed to evaluate the performance and safety of the AspireSR generator and its IntelliSense™ cardiac-based seizure detection feature.

Prof. Boon and clinical research colleagues at 13 other European centers implanted a total of 31 patients with the investigational AspireSR generator, which provides "normal mode" VNS Therapy augmented by seizure response stimulation.  After the implant procedure and initial stimulation adjustment period, patients were admitted to an epilepsy monitoring unit for up to five days and monitored to identify seizures and collect heart-rate data. 

The study met its primary endpoint in that the AspireSR generator, with IntelliSense cardiac-based seizure detection, detected more than 80% of seizures accompanied by ictal tachycardia (heart-rate increase) at a range of programmable settings.  The potential false detection rates were low.  The detections occurred close, and in some cases prior, to seizure onset, which may improve the effectiveness of the therapy.  In a clinical study evaluating 9,482 seizures, augmentation of VNS Therapy with manually-activated acute stimulation at seizure onset terminated 24% of seizures and diminished the severity or duration of another 38% of seizures 1.  The recently published evidence-based guideline update by the American Academy of Neurology on the use of VNS Therapy in epilepsy includes a recommendation that acute stimulation may be associated with seizure termination when used at the time of seizure auras 2. The safety profile for the AspireSR generator is consistent with currently available VNS Therapy systems. 

"The E-36 study demonstrated the accuracy of the cardiac-based seizure detection algorithm for seizures with heart rate changes," said Prof. Boon.  "Triggering stimulation when a seizure is detected should benefit patients with refractory epilepsy given the evidence that on-demand stimulation using the magnet can acutely interfere with seizure activity."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs